PDCD1 and neoplasm: When combined with checkpoint inhibition, OMCPmutIL-2 substantially improved survival of mice that received concomitant anti–CTLA-4, resulting in tumor regression in 3 out of 5 mice, while PD-1 blockade potentiated IL-15–based immunotherapy (Figure 9D).